An interventional study of cognitive-behavioral therapy and Wait first, then cognitive-behavioral therapy in Inflammatory Bowel Disease (IBD) and Cognitive Behavior Therapy, sponsored by Wang Zhen. Not yet recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2025-04-16.
Sponsored by Wang Zhen · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 114 studies in Inflammatory Bowel Diseases with a site in China — 51 open to participants now, 55 under way, 5 of them phase 3. Inflammatory Bowel Diseases · China.
Among the 114 studies in Inflammatory Bowel Diseases with a site in China, this one is the 50th largest by planned enrollment of the 60 interventional ones that give a count, is one of 26 that started in 2025, is one of 28 with no phase, reaches primary completion later than 27 of the 54 other live ones, and was the 71st registered.
1,555 studies on the registry are indexed under Inflammatory Bowel Diseases; 425 are open to participants now.
Browse Inflammatory Bowel Diseases studies →51 of the 114 studies in Inflammatory Bowel Diseases with a site in China are open now. Recruiting first, the newest first:
Benethera (Shaoxing) Biotechnology Co., Ltd. · Sites in China
Ages 18–55 · Healthy volunteers
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–80
First Affiliated Hospital of Kunming Medical University · Sites in China
Ages 18–60
Changhai Hospital · Sites in China
Ages 18–75
InSilico Medicine Hong Kong Limited · Sites in China
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 276 Inflammatory Bowel Diseases studies recruiting now, 134 (49%) set no upper age limit and 114 (41%) stop at 75 or younger; 75 take children under 18; 60 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
114 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 14 · Phase 3 9
First in 2009; this study’s year is marked. 26 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 68 across 875 interventional studies indexed under Inflammatory Bowel Diseases.
Median enrollment 97 across the 60 interventional studies, 148 across the 54 observational. Of the 35 that completed or were terminated, 6 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 114 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Wang Zhen as lead sponsor.
Wang Zhen has 1 study filed under Inflammatory Bowel Diseases — fewer than ten, so there is no comparison to draw.
13 of the studies in Inflammatory Bowel Diseases with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06713694Wang ZhenThe Impact of Culture in Cognitive Behavior Therapy (CBT) for Patients With Inflammatory Bowel Disease | 2026-12-30 |
| NCT07632573Benethera (Shaoxing) Biotechnology Co., Ltd.A Phase I Study to Evaluate the Safety/Tolerability of BDHK-2009 Tablets in Healthy Adult | 2026-12-31 |
| NCT07165470Changhai HospitalPre-Packaged Low-Residue Diet Assisting Bowel Preparation in Patients With Inflammatory Bowel Disease | 2026-12-31 |
| NCT06483373Shanghai Pharmaceuticals Holding Co., LtdA Clinical Study of SPH7854 Granules in Healthy Subjects. | 2026-12-31 |
| NCT04187820Shanghai Institute of Acupuncture, Moxibustion and MeridianEffect of Acupuncture on Mild to Moderate Active Crohn's Disease | 2026-12-31 |
Add all 13 to your calendar (.ics) → With an account.
Among the 114 studies in Inflammatory Bowel Diseases with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Introduction Inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis, is a chronic condition that affects the gastrointestinal tract and has a significant impact on patients' quality of life (QoL) and mental health(Barberio, Zamani et al. 2021). Cognitive behavioral therapy (CBT) has been recognized as a potential therapeutic approach to address the psychological comorbidities associated with IBD(Seaton, Hudson et al. 2024). However, the effectiveness of CBT in IBD is not solely a clinical issue but is also intertwined with cultural factors that can influence treatment outcomes(Naeem 2019).
The effectiveness of CBT in IBD is not solely a clinical issue but is also intertwined with cultural factors that can influence treatment outcomes . This has implications for the delivery of CBT in IBD care, as cultural beliefs and values can affect help-seeking behaviors and responses to treatment. Cultural factors are integral to the successful implementation of CBT in IBD care(Hinton and Patel 2017, Naeem, Sajid et al. 2023). Further research is needed to understand how cultural adaptations can enhance the efficacy of CBT for IBD patients from diverse backgrounds. It is essential to consider cultural nuances in the development and delivery of CBT to ensure that it is both effective and acceptable to patients with IBD across different cultures.
Objective: To identify gaps in the current understanding of the role of culture in CBT for IBD, including the variety of cultural contexts and IBD populations studied . To provide insights that can guide clinical practice in offering culturally competent CBT to IBD patients and inform policy decisions regarding mental health services for diverse populations with IBD .
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other: cognitive-behavioral therapy
Other: cognitive-behavioral therapy
Other: Wait first, then cognitive-behavioral therapy
Other: Wait first, then cognitive-behavioral therapy
The treatment will consist of eight weekly sessions, each lasting one hour. The first session will focus on the rationale of cognitive behavioral therapy, i.e. the influence of (irrational or dysfunctional) cognitions and attitudes on (restrictive) feelings and behaviors. Additionally, goal setting will be initiated. Since patients may have a wide diversity of psychiatric problems (i.e. PTSD, anxiety disorders and depression), the treatment manual will encompass five optional modules for the therapist that focus on each of these disorders (i.e. exposure based for anxiety and PTSD, behavioral activation for depression). The subsequent sessions (2-6) will target teaching the patient to identify and challenge dysfunctional cognitions and attitudes related to IBD. Each session will address specific illness-related cognitions. If possible, dysfunctional cognitions and attitudes will be replaced by helpful cognitions and attitudes.
participants assigned to the waiting-list control condition will wait 3.5 months before they are treated with CBT. This period corresponds to the duration of the CBT intervention and follow-up assessment of the experimental group. After this 3.5 month waiting period the participants in the waiting-list control condition will be asked to complete a follow-up after waiting/baseline before CBT assessment before starting treatment.
mood
anxiety and depression Generalized Anxiety Disorder-7 Item Scale(GAD-7) and Patient Health Questionnaire-9 Scale (PHQ-9) assesses the possible presence of anxiety and depressive states. The GAD-7 and PHQ-9 is considered to be unbiased by the presence of somatic illness and is found to be reliable and valid . It consists of two sub-scales, anxiety and depression, both containing seven items.
Time frame: From enrollment to the end of treatment at 8 weeks
stigma
The Social Impact Scale (SIS) was used to evaluate stigma associated with wound malodor. The SIS is widely used in patients with chronic diseases and includes 24 items within four dimensions, social exclusion, economic discrimination, inner sense of shame, and social isolation, evaluated using a Likert4 method. Total possible score ranged from 24 points to 96 points, with higher scores associated with a greater perceived social impact.
Time frame: From enrollment to the end of treatment at 6 weeks
Start is estimated for Aug 2025; primary completion for Dec 2026, 16 months later.
Of 285 non-industry interventional studies with no phase under Inflammatory Bowel Diseases, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 50. This study's planned 16 months is below that.
Counting every sponsor, half of 299 studies reached it within 26 months; a quarter within 14 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.